New therapies for obesity

Research output: Contribution to journalReviewpeer-review

Documents

Obesity is a chronic disease associated with serious complications and increased mortality. Weight loss (WL) through lifestyle changes results in modest WL long-term possibly due to compensatory biological adaptations (increased appetite and reduced energy expenditure) promoting weight gain. Bariatric surgery was until recently the only intervention that consistently resulted in >= 15% WL and maintenance. Our better understanding of the endocrine regulation of appetite has led to the development of new medications over the last decade for the treatment of obesity with main target the reduction of appetite. The efficacy of semaglutide 2.4 mg/week-the latest glucagon-like peptide-1 (GLP-1) receptor analogue-on WL for people with obesity suggests that we are entering a new era in obesity pharmacotherapy where >= 15% WL is feasible. Moreover, the WL achieved with the dual agonist tirzepatide (GLP-1/glucose-dependent insulinotropic polypeptide) for people with type 2 diabetes and most recently also obesity, indicate that combining the GLP-1 with other gut hormones may lead to additional WL compared with GLP-1 receptor analogues alone and in the future, multi-agonist molecules may offer the potential to bridge further the efficacy gap between bariatric surgery and the currently available pharmacotherapies.

Original languageEnglish
JournalCardiovascular Research
Volume119
Issue number18
Pages (from-to)2825–2842
ISSN0008-6363
DOIs
Publication statusPublished - 2023

    Research areas

  • Obesity, Pharmacotherapy, Bariatric surgery, Semaglutide, Tirzepatide, Liraglutide, LIFE-STYLE INTERVENTION, GLP-1 RECEPTOR AGONIST, LIRAGLUTIDE 3.0 MG, QUALITY-OF-LIFE, CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE, CARDIOVASCULAR RISK-FACTORS, TYPE-2 DIABETES-MELLITUS, WEIGHT-LOSS MAINTENANCE, SEMAGLUTIDE 2.4 MG, POST-HOC ANALYSIS

ID: 330888777